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Abstract
Background: Increased platelet reactivity has been implicated in cardiovascular disease – the
major cause of death in patients with end stage renal disease (ESRD). FcGammaRIIA is a component
of glycoprotein VI and Ib-IX-V that mediate activation of platelets by collagen and von Willebrand
factor. To determine whether expression of FcGammaRIIA impacts platelet reactivity we quantified
its expression and platelet reactivity in 33 patients with ESRD who were undergoing hemodialysis.
Methods:  Blood samples were obtained from patients immediately before hemodialysis and
before administration of heparin. Platelet expression of FcGammaRIIA and the activation of
platelets in response to low concentrations of convulxin (1 ng/ml, selected to mimic effects of
collagen), thrombin (1 nM), adenosine diphosphate (ADP, 0.2 uM), or platelet activating factor
(PAF, 1 nM) were determined with the use of flow cytometry in samples of whole blood
anticoagulated with corn trypsin inhibitor (a specific inhibitor of Factor XIIa).
Results: Patients were stratified with respect to the median expression of FcGammaRIIA. Patients
with high platelet expression of FcGammaRIIA exhibited 3-fold greater platelet reactivity compared
with that in those with low expression in response to convulxin (p < 0.01) and 2-fold greater
activation in response to thrombin, ADP, and PAF (p < 0.05 for each). For each agonist, expression
of FcGammaRIIA correlated modestly but positively with platelet reactivity. The strongest
correlation was with thrombin-induced activation (r = 0.6, p < 0.001).
Conclusion: Increased platelet reactivity in response to low concentrations of diverse agonists is
associated with high expression of FcGammaRIIA and may contribute to an increased risk of
thrombosis in patients with ESRD.
Background
Cardiovascular disease is the major cause of death in
patients with end stage renal disease (ESRD) accounting
for nearly 50% of deaths [1]. Patients undergoing long-
term dialysis have a particularly poor rate of survival after
myocardial infarction [2]. We and others have found that
platelet reactivity (i.e. the propensity of platelets to acti-
vate) is increased in patients with ESRD undergoing
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hemodialysis [3-5]. Increased platelet reactivity has been
associated with an increased risk of subsequent cardiac
events [6-8]. Accordingly, one factor contributing to a
greater risk of cardiovascular disease and death in patients
with ESRD may be increased platelet reactivity.
Numerous Fc receptors are known. All are members of the
immunoglobulin superfamily. Human platelets express
one, an FcγR encoded by the FcγRIIa gene [9]. FcγRIIa is a
component of both the glycoprotein (GP) VI receptor that
mediates activation of platelets by collagen [10] and the
GP Ib-IX-V receptor that mediates activation of platelets
by von Willebrand Factor [11]. Increased platelet expres-
sion of FcγRIIa has been seen in patients with diabetes
[12] and ESRD [13], conditions known to be at an
increased risk for cardiovascular disease. Increased expres-
sion has been observed in patients who have experienced
coronary or cerebral thrombosis [14] and was associated
with a greater incidence of arterial thrombotic events in
patients with ESRD [13]. FcγRIIa appears to participate in
thrombotic complications associated with the severe form
of heparin-induced thrombocytopenia/thrombosis
(HITT) [15].
The present study was performed to determine whether
platelet expression of FcγRIIa correlates with platelet reac-
tivity in patients with ESRD undergoing hemodialysis.
Expression of FcγRIIa and platelet reactivity were deter-
mined with the use of flow cytometry. Platelet reactivity
was determined in response to convulxin (a snake venom
that mimics the effects of collagen on GP VI [16]) as well
as to adenosine diphosphate (ADP), thrombin, or platelet
activating factor (PAF).
Methods
Subjects
In a protocol approved by the University of Vermont Insti-
tutional Review Board, 33 subjects were enrolled after
written informed consent had been obtained. Eligible
patients were those of more than 18 years of age who were
undergoing hemodialysis for ESRD. Patients were
excluded if they had an intercurrent illness such as pneu-
monia or congestive heart failure, any hematological dis-
order, a terminal illness with expected survival of less than
6 months, or the inability to provide informed consent.
No patient had experienced a recent (within 1 month)
thrombotic event.
Collection of blood samples
Blood samples were obtained from the dialysis catheter
immediately after its insertion into the arterial portion of
the arteriovenous fistula and before administration of an
anticoagulant. We have found that taking blood from a
catheter does not per se influence assessment of platelet
function [3,6]. All blood samples were drawn into
syringes containing corn trypsin inhibitor (CTI, 32 μg/ml,
1:10 V/V, Enzyme Research, South Bend, IN) with the use
of the two-syringe technique. CTI is a specific inhibitor of
coagulation factor XIIa [17] and was used as the anticoag-
ulant to avoid altered activation of platelets by conven-
tionally used anticoagulants such as citrate [18].
Determination of platelet reactivity
Assays were performed by adding 5 μl of whole blood to
microcentrifuge tubes containing 60 μl of HEPES-Tyrodes
buffer (5 mM HEPES, 137 mM NaCl, 2.7 mM NaHCO3,
0.36 mM NaH2PO4, 2 mM CaCl2, 4 mM MgCl2, and 5
mM dextrose, pH 7.4), fluorochrome-labeled ligands, the
peptide GPRP (Gly-Pro-Arg-Pro) to prevent polymeriza-
tion of endogenous fibrinogen [19] and agonist. A perid-
inin chlorophyll protein (per-CP) conjugated antibody to
GP IIIa (CD61, Becton Dickinson, San Jose, California)
was used as an activation-independent marker of plate-
lets. This antibody does not inhibit binding of fibrinogen
to the activated conformer of GP IIb-IIIa. A fluorescein
isothiocyanate (FITC) conjugated PAC-1 antibody (Bec-
ton Dickinson) was used to assess activation (conforma-
tion change) of GP IIb-IIIa. A phycoerythrin (PE)
conjugated antibody to P-selectin (CD62, Becton Dickin-
son) was used to assess surface expression of P-selectin
associated with α-granule degranulation. We used con-
centrations of each agonist that induce sub-maximal acti-
vation because we have shown previously that such
concentrations effectively delineate inter-individual dif-
ferences in platelet reactivity [6]. Agonists included
thrombin (1 nM, Haematologic Technologies Inc, Essex
Junction, VT), ADP (0.2 μM, BioData, Horsham PA), PAF
(1 nM, Sigma, St. Louis, MO), and convulxin (1 ng/ml,
Pentapharm, Basel Switzerland)
The reaction mixture was incubated at room temperature
for 15 minutes. Subsequently, platelets were fixed, and the
red cells were lysed by the addition of 100 μl of Optilyse-
C (1.5% formadehyde, Immunotech, Wesbrook, Maine).
All assays were performed in duplicate. We have demon-
strated previously that the intra-assay coefficient of varia-
tion is less than 10% [20]. To assess the extent of
nonspecific association of proteins with platelets, blood
was added to control tubes with FITC-labeled and PE-
labeled non-immune immunoglobulins. Flow cytometric
analysis was performed with a fluorescence-activated cell
sorter (Epics Elite EPS, Coulter). The population of plate-
lets was identified on the basis of particle size (forward
and 90° side scatter) and the association with CD 61 anti-
body. The control ligands (non-immune immunoglobu-
lins) were used for determination of a threshold above
which activation-dependent binding was present. Plate-
lets for which binding exceeded the threshold were iden-
tified as activated, and results were reported as theThrombosis Journal 2007, 5:7 http://www.thrombosisjournal.com/content/5/1/7
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percentage of platelets activated with respect to binding of
PAC-1 and surface expression of P-selectin.
Expression of FcγRIIa
Platelet expression of FcγRIIa was quantified with the use
of flow cytometry. Blood (5 μl) was added to 60 μl of
HEPES-Tyrodes buffer (described above) plus antibodies.
Platelets were identified as described above on the basis of
size and with the use of a PerCP-conjugated anti-CD61.
FcγRIIa expression was quantified with a primary goat
anti-Fcγ RIIA/CD32a (0.2 mg/ml, R&D Systems, Minne-
apolis, MN) and a secondary PE-conjugated anti-goat IgG
(10:1 ratio of secondary to primary antibody, Jackson
ImmunoResearch Laboratories, West Grove PA). Assay of
the expression of FcγRIIa was performed in duplicate. A
control assay tube that contained only secondary anti-
body was used to quantify non-specific association of sec-
ondary antibody with platelets. Mean fluorescence
intensity (MFI) was used to quantify expression of
FcγRIIa, and the expression of FcγRIIa was quantified by
subtracting the MFI in the control tube from the average
total MFI determined in the assay tubes containing both
primary and secondary antibodies. Preliminary experi-
ments were performed to demonstrate that the concentra-
tion of primary antibody and the ratio of primary to
secondary antibody yielded the greatest sensitivity for
detection of expression of FcγRIIa.
Statistical analysis
Values are means ± SD. Differences in platelet function
were identified with the use of a Student's t tests. Categor-
ical variables were compared with the use of chi squared
analysis. Significance of linear regressions was assessed
with the use of analysis of variance. Significance was
defined as p < 0.05.
Results
The clinical characteristics of the patients studied are
shown in table 1. Expression of FcγRIIa by platelets from
the patients studied is shown in figure 1. A skewed distri-
bution of expression of FcγRIIa is evident with 50% of the
patients exhibiting an MFI less than 1.2. By contrast, plate-
let expression of FcγRIIa ranged from 1.2 to 22 in the
remaining patients.
Platelet reactivity
Patients were stratified into 2 groups on the basis of the
median expression of FcγRIIa. Activation of platelets was
identified by both the surface expression of P-selectin (fig-
ure 2) and the binding of PAC-1 to the activated con-
former of GP IIb-IIIa (figure 3). Activation of platelets in
response to the collagen mimetic, convulxin, was 3-fold
greater in the patients with high FcγRIIa expression (p <
0.01, figure 2 and 3). Increased expression of FcγRIIa was
associated with approximately 2-fold greater platelet reac-
tivity in response to ADP, thrombin, or PAF (p < 0.05 for
each, figure 2 and 3). Accordingly, patients with high
FcγRIIa expression exhibited greater platelet reactivity in
response to each of the agonists.
Diverse genetic and environmental stimuli influence
platelet reactivity. Nevertheless, platelet reactivity in
response to each of the agonists correlated modestly but
significantly with platelet expression of FcγRIIa (figure 4).
The strongest correlation was with thrombin-induced acti-
vation (r = 0.6, p < 0.001).
Discussion
Our results demonstrate that platelet expression of FcγRIIa
varies substantially in patients with ESRD undergoing
hemodialysis. Distribution of platelet expression of
FcγRIIa was skewed with some patients exhibiting sub-
stantially greater platelet expression of FcγRIIa. Greater
expression of FcγRIIa was associated with an increased
propensity for activation (i.e. increased platelet reactivity)
in response to each agonist tested. These results suggest
that in addition to its direct participation in the activation
of platelets induced by collagen and von Willebrand fac-
tor, greater FcγRIIa expression increases platelet reactivity.
Increased platelet reactivity has been associated with a
greater risk of cardiovascular events [6-8,13]. Accordingly,
our results demonstrating an association between greater
platelet expression of FcγRIIa and increased platelet reac-
tivity are consistent with a previous report demonstrating
that increased expression of FcγRIIa is associated with a
greater risk of arterial thrombotic events in patients with
ESRD [13].
FcγRIIa is a component of both the GP VI and GP Ib-IX-V
receptors on the platelet surface. GP VI is composed of
two GP VI molecules and an FcγRIIa dimer [10]. GP VI
forms a dimeric complex that exhibits high affinity bind-
ing to collagen. Activation of GP VI is initiated by tyrosine
phosphorylation of the immunoreceptor tyrosine-based
activation motif (ITAM) of FcγRIIa, and subsequent tyro-
sine phosphorylation of signaling proteins leads to activa-
tion of platelets. Activation of platelets by GP Ib-IX-V is
not completely understood. FcγRIIa co-localizes with GP
Ib-IX-V [21] and participates in but may not be essential
to GP Ib-IX-V-induced activation of platelets [11]. Bacteria
such as staphylococcus aureus and group B streptococcus
can induce activation of platelets through direct interac-
tion with FcγRIIa [22,23]. Thus, FcγRIIa can participate in
the activation of platelets directly as well as by serving as
a component of the receptors for collagen and von Wille-
brand factor.
Our results demonstrate that increased expression of
FcγRIIa is associated with greater platelet reactivity in
response to exposure of platelets to diverse stimuli includ-Thrombosis Journal 2007, 5:7 http://www.thrombosisjournal.com/content/5/1/7
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ing ADP, thrombin and PAF. We used convulxin to mimic
the effects of collagen because collagen-induced activa-
tion is not efficient in our system which does not employ
sheer forces or stirring [18]. Convulxin, like collagen, acti-
vates platelets through interaction with GP VI [16]. Con-
sistent with the pivotal role of FcγRIIa in GP VI mediated
activation of platelets as well as the results obtained by
others with collagen [12,14], we saw greater activation of
platelets by convulxin when the expression of FcγRIIa was
increased. Greater activation in response to ADP,
thrombin, and PAF was unexpected. The similar, albeit
modest, correlation between platelet expression of FcγRIIa
and activation in response to each of the agonists suggests
that the effects of FcγRIIa on the activation of platelets are
not confined to those mediated by interactions involving
the GP VI or the GP Ib-IX-V receptor but rather influence
activation by diverse receptors. Evidence that bacteria can
directly activate platelets through direction interaction
with FcγRIIa [22,23] and that FcγRIIa may not be essential
to GP Ib-IX-V-induced activation of platelets [11], demon-
strate that expression of FcγRIIa is not solely a reflection of
the density of GP VI and GP Ib-IX-V. These observations
in combination with our results suggest that platelet
expression of FcγRIIa has an independent influence on
platelet reactivity.
FcγRIIa has not been reported to be a component of sign-
aling induced by ADP receptors (P2Y1 or P2Y12),
thrombin receptors (protease activated receptor [PAR] 1
and 4) or the PAF receptor. Nevertheless, the phenome-
non of increased activation induced by multiple agonists
has been recognized previously. For example, maximal
activation of the GTPase Rac [24] and maximal activation
of platelets occur when both FcγRIIa and the P2Y12 recep-
tor are activated [25]. These observations suggest that ADP
released by platelets [26] when they are activated may
contribute to activation induced by agonists that activate
Expression of FcγRIIa by platelets from 33 patients with  ESRD undergoing hemodialysis Figure 1
Expression of FcγRIIa by platelets from 33 patients with 
ESRD undergoing hemodialysis. Expression of FcγRIIa was 
determined with the use of flow cytometry. FcγRIIa MFI was 
quantified by subtracting the mean fluorescence intensity 
(MFI) seen with secondary antibody alone from the MFI seen 
with both the primary and secondary antibody. A skewed 
distribution is apparent with 50% of the patients exhibiting 
low expression (MFI<1.2).
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Table 1: Clinical characteristics of patients
Characteristic Low FcγRIIa High FcγRIIa
n (%) n (%) p value
Age (mean ± SD) 67 ± 15 67 ± 12 1
male 8 (50%) 10 (63%) 0.87
CAD 11 (71%) 10 (63%) 0.82
CVA/TIA 2 (12%) 7 (44%) 0.15
Hypertension 13 (76%) 16 (100%) 0.55
Diabetes 10 (61%) 10 (63%) 0.89
Hyperlipidemia 11 (65%) 9 (56%) 0.57
Treatment with
aspirin 9 (53%) 11(69%) 0.89
warfarin 3 (18%) 3 (19%) 0.71
thienopyridine 3 (18%) 5 (31%) 0.64
β blocker 8 (47%) 11 (69%) 0.36
Calcium blocker 7 (41%) 5 (31%) 0.81
ACEI/ARB 7 (41%) 4 (25%) 0.55
insulin 5 (29%) 7 (44%) 0.59
oral hypoglycemic 3 (18%) 3 (19%) 0.71
Duration of HD (mo – mean ± SD) 31 ± 25 32 ± 23 0.91
CAD = coronary arterial disease, CVA = cerebrovascular accident, TIA = transient ischemic attack, ACEI = angiotensin converting enzyme 
inhibitor, ARB = angiotensin receptor blocker, HD = hemodialysis, mo = monthThrombosis Journal 2007, 5:7 http://www.thrombosisjournal.com/content/5/1/7
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FcγRIIa and are consistent with the contribution of ADP to
thrombin-induced activation of platelets [27].
We did not see greater activation of platelets in the
absence of agonist in patients with increased expression of
FcγRIIa. A limited (< 5%) and similar number of platelets
in patients with high and patients with low expression of
FcγRIIa exhibited evidence of activation in the absence of
agonist. Our results are consistent with those in a recent
report demonstrating that FcγRIIa participates in the acti-
vation of platelets induced by low but not high concentra-
tions of thrombin [28]. Thus, it appears that increased
expression of FcγRIIa primes platelets for activation by
low concentrations of diverse agonists.
Our results were obtained with blood from 33 subjects.
The limited sample size prevents definitive exclusion of
potentially confounding variables. Additional studies
with more patients and correlation with the incidence of
clinical events will be necessary to determine the impact
of platelet expression of FcγRIIa on platelet function and
the risk of arterial thrombotic events.
The mechanism(s) responsible for high expression of
FcγRIIa that was seen in 50% of our patients with ESRD
was not determined. Although genetic predisposition may
contribute, the high expression seen in patients with
ESRD [13] as well as those with acute coronary and cere-
brovascular events [14] and those with diabetes [12]
implicates factors other than genetics as determinants of
expression. Neutrophil expression of FcγRIIa is increased
by tumor necrosis factor alpha [29]. Thus, expression of
FcγRIIa may be regulated dynamically by multiple factors.
Accordingly, elucidation of factors that increase expres-
sion of FcγRIIa in patients with ESRD treated with hemo-
dialysis may identify novel pharmacologic targets that can
decrease platelet reactivity and reduce the incidence of car-
diovascular events.
Conclusion
We found that patients with ESRD treated with hemodial-
ysis who exhibit high platelet expression of FcγRIIa exhibit
increased platelet reactivity. Increased platelet reactivity is
associated with an increased risk of cardiac events [6-
8,13]. Thus, our results are consistent with a previous
report that found that increased platelet expression of
FcγRIIa was associated with a greater incidence of arterial
thrombotic events in patients with ESRD [13]. Pharmaco-
Activation of platelets identified by the binding of the anti- body PAC-1 to the activated conformer of GP IIb-IIIa Figure 3
Activation of platelets identified by the binding of the anti-
body PAC-1 to the activated conformer of GP IIb-IIIa. 
Patients with ESRD (n = 33) were stratified into 2 groups on 
the basis of median expression of FcγRIIa. Activation of plate-
lets was quantified with the use of flow cytometry to define 
the percentage of platelets that bound PAC-1 in the absence 
of agonist and in response to the collagen mimetic convulxin 
(1 ng/ml), PAF (1 nM), ADP (0.2 μM), or thrombin (1 nM). 
Patients with high expression of FcγRIIa did not exhibit 
greater activation of platelets in the absence of agonist but 
did exhibit greater activation in response to each of the ago-
nists used.
no agonist convulxin PAF ADP thrombin
p
e
r
c
e
n
t
a
g
e
 
o
f
 
p
l
a
t
e
l
e
t
s
 
a
c
t
i
v
a
t
e
d
(
b
i
n
d
i
n
g
 
o
f
 
P
A
C
-
1
)
0
20
40
60
80
100
low FcγRIIa
high FcγRIIa
p<0.01
p<0.05
p<0.05
p<0.05
Activation of platelets identified by surface expression of P- selectin Figure 2
Activation of platelets identified by surface expression of P-
selectin. Patients with ESRD (n = 33) were stratified into 2 
groups on the basis of median expression of FcγRIIa. Activa-
tion of platelets was quantified with the use of flow cytome-
try for delineation of the percentage of platelets expressing 
P-selectin on their surface in the absence of agonist and in 
response to the collagen mimetic convulxin (1 ng/ml), PAF (1 
nM), ADP (0.2 μM), or thrombin (1 nM). Patients with high 
expression of FcγRIIa did not exhibit greater activation of 
platelets in the absence of agonist but did exhibit greater 
activation in response to each of the agonists used.
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logic modification of expression of FcγRIIa may be a
promising prophylactic target.
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The correlation of platelet reactivity with expression of FcγRIIa Figure 4
The correlation of platelet reactivity with expression of FcγRIIa. Activation of platelets was identified with the use of flow 
cytometry to delineate surface expression of P-selectin in response to exposure of the platelets to the collagen mimetic con-
vulxin (1 ng/ml), PAF (1 nM), ADP (0.2 μM), or thrombin (1 nM). Expression of FcγRIIa was quantified with the use of flow 
cytometry by subtracting the MFI seen with secondary antibody alone from the MFI seen with both the primary and secondary 
antibody. Significant and similar, although modest correlations (r values ranging from approximately 0.4–0.6) were seen with 
each of the agonists used.
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